Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16002007 | 1.00 | EPHX2 (0.41) | EPHX2SPHK1KDM4EKDM1ALMNA | |
| SCHEMBL701060 | 0.89 | — | — | |
| SCHEMBL18045582 | 0.89 | SPHK1 (0.42) | SPHK1KDM4EKDM1ADPP4 | |
| Bromide SCHEMBL2833578 | 0.87 | — | — | |
| SCHEMBL1796153 | 0.86 | KDM4E (0.40) | EPHX2SPHK1KDM4ELMNAGBA1 | |
| SCHEMBL1484842 | 0.79 | — | — | |
| SCHEMBL3429410 | 0.79 | — | — | |
| SCHEMBL24429571 | 0.78 | ALDH1A1 (0.41) | SPHK1KDM4EKDM1ATSHR | |
| SCHEMBL1795636 | 0.78 | EPHX2 (0.39) | EPHX2KDM4ELMNAGBA1CYP1A2 | |
| SCHEMBL24429564 | 0.78 | ALDH1A1 (0.41) | SPHK1KDM4EKDM1ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9029448-B2 | Method for preparing aqueous suspensions of mineral materials using amines in combination with vinyl-carboxylic polymers | OMYA INTERNATIONAL AG (CH) | 2015-05-12 | — | — | US | claimed |
| US-8545617-B2 | Neutralizing and co-dispersion agent with strong capacity for developing coloring power, and paints and pigment concentrates containing same | ARKEMA FRANCE (FR) | 2013-10-01 | — | — | US | claimed |
| EP-2640786-A1 | METHOD FOR PREPARING AQUEOUS SUSPENSIONS OF MINERAL MATERIALS USING AMINES IN COMBINATION WITH VINYL CARBOXYLIC POLYMERS | Omya Development AG (CH) | 2013-09-25 | — | — | EP | claimed |
| EP-2455429-B1 | Method for preparing aqueous suspensions of mineral materials using amines combined with vinyl carboxylic polymers | OMYA DEVELOPMENT AG (CH) | 2013-08-14 | — | — | EP | claimed |
| US-20120129986-A1 | USE OF AMINES IN COMBINATION WITH ACRYLIC POLYMERS IN THE MANUFACTURE OF AQUEOUS SUSPENSIONS OF MINERAL MATTERS | COATEX S.A.S. (FR) | 2012-05-24 | — | — | US | claimed |
| WO-2012066410-A1 | METHOD FOR PREPARING AQUEOUS SUSPENSIONS OF MINERAL MATERIALS USING AMINES IN COMBINATION WITH VINYL CARBOXYLIC POLYMERS | OMYA DEVELOPMENT AG (CH) | 2012-05-24 | — | — | WO | claimed |
| EP-2455429-A1 | Method for preparing aqueous suspensions of mineral materials using amines combined with vinyl carboxylic polymers | Omya Development AG (CH) | 2012-05-23 | — | — | EP | claimed |
| US-20120024193-A1 | NEUTRALIZING AND CO-DISPERSION AGENT WITH STRONG CAPACITY FOR DEVELOPING COLORING POWER, AND PAINTS AND PIGMENT CONCENTRATES CONTAINING SAME | ARKEMA FRANCE (FR) | 2012-02-02 | — | — | US | claimed |
| EP-2227316-A2 | NEUTRALISATION AND CO-DISPERSION AGENT HAVING A HIGH COLOURING-POWER ENHANCEMENT CAPACITY, AND PAINTS AND PIGMENT CONCENTRATES CONTAINING SAME | ARKEMA FRANCE (FR) | 2010-09-15 | — | — | EP | claimed |
| WO-2009087330-A2 | NEUTRALISATION AND CO-DISPERSION AGENT HAVING A HIGH COLOURING-POWER ENHANCEMENT CAPACITY, AND PAINTS AND PIGMENT CONCENTRATES CONTAINING SAME | ARKEMA FRANCE (FR) | 2009-07-16 | — | — | WO | claimed |
| US-20230286902-A1 | LIPID NANOPARTICLE COMPOSITION | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-09-14 | — | — | US | disclosed |
| WO-2023098842-A1 | NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM SARS-CoV-2 OMICRON STRAIN | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023056911-A1 | MULTIVALENT NUCLEIC ACID VACCINES FOR CORONAVIRUS BASED ON SEQUENCES DERIVED FROM SARS-CoV-2 BETA AND DELTA STRAINS | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2023-04-13 | — | — | WO | disclosed |
| US-11472766-B2 | Lipid nanoparticle composition | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2022-10-18 | — | — | US | disclosed |
| US-20220153686-A1 | LIPID NANOPARTICLE COMPOSITION | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2022-05-19 | — | — | US | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
| US-6004669-A | ELECTROSTATIC CHARGING MEMBER, UNIFORMLY DISPERSED IN A MODIFIED RESIN AS A BASE POLYMER BEING MODIFIED BY AN AMINE GROUP WHICH HAS AN ACID-BASE INTERACTION WITH THE OXIDATION-PROCESSED ELECTRICALLY-CONDUCTING AGENT, | FUJI XEROX CO., LTD. (JP) | 1999-12-21 | — | — | US | disclosed |
| US-4211699-A | FROM A DIISOCYANATE, AN AMINO- OR HYDRAZINO DIOL, AND A MASKING LACTAM | BAYER AKTIENGESELLSCHAFT (DE) | 1980-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286902-A1 | LIPID NANOPARTICLE COMPOSITION | CETP, NPC1, LCAT | EPHX2 2487/4885SPHK1 1219/4885KDM4E 4495/4885 |
| US-20220153686-A1 | LIPID NANOPARTICLE COMPOSITION | CETP, NPC1, LCAT | EPHX2 2487/4885SPHK1 1219/4885KDM4E 4495/4885 |
| US-11472766-B2 | Lipid nanoparticle composition | CETP, NPC1, LCAT | EPHX2 2487/4885SPHK1 1219/4885KDM4E 4495/4885 |
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | EPHX2 3994/4885SPHK1 2758/4885KDM4E 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.